BRCA1 Mutation Testing: Controversies and Challenges (Editorial) BRCA1 Mutation Testing: Controversies and Challenges (Editorial)

BRCA1 Mutation Testing: Controversies and Challenges (Editorial‪)‬

Clinical Chemistry 1997, Jan, 43, 1

    • 2,99 €
    • 2,99 €

Publisher Description

Breast cancer is a leading cause of significant morbidity and mortality for women. Methods to reliably detect the earliest stages of breast cancer have been widely sought because the success of breast cancer treatment is influenced by how early a malignancy is diagnosed. Current methods for early detection rely on either physical examination to palpate a tumor or radiography. The development of genetic tests that enable accurate risk assessment for individuals in high-risk families has been predicted to have substantial medical benefits. Significant and unprecedented media fanfare informed both medical professionals and the general public about exciting new discoveries in breast cancer genetics, namely, identification of two critically important breast cancer genes BRCA1 and BRCA2, helping to create an immediate demand for clinical tests for these genes. The identification of genetic alterations underlying the development of breast cancer has ushered in an exciting and challenging new era in oncology, genetics, and molecular diagnostics. DNA diagnostic tests for breast cancer genes, including BRCA1, BRCA2, and TP53 (which causes breast cancer in the context of the Li-Fraumeni cancer predisposition syndrome), are currently available in most cases only for individuals who have clear family histories of one of the hereditary breast cancer syndromes. Presymptomatic DNA-based assessment for breast cancer risk has had only limited use in clinical practice to date. In cases of autosomal dominant breast cancer (~5% of all breast cancers), identification of the specific BRCA disease-causing mutation has enabled more-accurate risk-modification counseling for first-degree relatives and facilitated susceptibility testing for family members. Presymptomatic identification of a germ-line BRCA mutation provides individuals with specific, if not yet well studied, options for preventive medical management. For example, initial studies indicate that women who have inherited a mutant BRCA1 allele from an affected mother have a markedly increased risk of developing breast cancer (~85% lifetime risk) or ovarian cancer (~50% lifetime risk) or both [1-5]. These women may choose either increased medical surveillance to detect and treat early tumors or bilateral prophylactic mastectomies and (or) oophorectomies in an attempt to eradicate the tissues that have the greatest potential of becoming malignant. Both choices are associated with some morbidity, and neither choice, unfortunately, absolutely guarantees cancer-free survival.

GENRE
Science & Nature
RELEASED
1997
1 January
LANGUAGE
EN
English
LENGTH
11
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
PROVIDER INFO
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
164.3
KB
Alcohol Abuse and Carbohydrate-Deficient Transferrin Analysis: Are Screening and Confirmatory Analysis Required?(Letters) (Letter to the Editor) Alcohol Abuse and Carbohydrate-Deficient Transferrin Analysis: Are Screening and Confirmatory Analysis Required?(Letters) (Letter to the Editor)
2002
Distribution of Adiponectin, Leptin, And Metabolic Correlates of Insulin Resistance: A Longitudinal Study in British Children; 1: Prepuberty (Earlybird 15) (Endocrinology and Metabolism) (Clinical Report) Distribution of Adiponectin, Leptin, And Metabolic Correlates of Insulin Resistance: A Longitudinal Study in British Children; 1: Prepuberty (Earlybird 15) (Endocrinology and Metabolism) (Clinical Report)
2008
Plasminogen Activator Inhibitor 1 4G/5G Polymorphism and Coagulation Factor XIII Val34leu Polymorphism: Impaired Fibrinolysis and Early Pregnancy Loss (Molecular Diagnostics and Genetics) Plasminogen Activator Inhibitor 1 4G/5G Polymorphism and Coagulation Factor XIII Val34leu Polymorphism: Impaired Fibrinolysis and Early Pregnancy Loss (Molecular Diagnostics and Genetics)
2003
Detection of Antinuclear Antibodies by Solid-Phase Immunoassays and Immunofluorescence Analysis (Clinical Immunology) Detection of Antinuclear Antibodies by Solid-Phase Immunoassays and Immunofluorescence Analysis (Clinical Immunology)
2004
Metabolic, Nutritional, Iatrogenic, And Artifactual Sources of Urinary Organic Acids: A Comprehensive Table. Metabolic, Nutritional, Iatrogenic, And Artifactual Sources of Urinary Organic Acids: A Comprehensive Table.
2002
Doping in Sport: Misuse, Analytical Tests, And Legal Aspects (Editorial) Doping in Sport: Misuse, Analytical Tests, And Legal Aspects (Editorial)
1997